Tamryn Hassel, MBA Pharmaceutical Consultant & Compliance Trainer | Building Excellence & Quality Reputation | Transforming Knowledge into Action with a Touch of Humour
Introduction
The Good Manufacturing Practice (GMP) guidelines are a set of principles that help to ensure products are produced consistently and controlled according to established quality standards. GMP covers all aspects of production, from starting materials, premises, and equipment to staff training and personal hygiene. Over the decades, GMP has evolved significantly, driven by technological advancements, changes in regulatory laws, and lessons learned from past industry failures. In this article, we explore the history and evolution of GMP and its impact on the pharmaceutical industry.
Evolution of GMP: Key Historical Milestones
In the early 20th century, the pharmaceutical industry was relatively unregulated, with a primary focus on mass production and a lack of quality control, leading to several public health crises. Significant events have marked the development of GMP. One of the earliest impactful events was the Massengill disaster in 1937, where 107 people, including many children, died after consuming Elixir Sulfanilamide, a cough medicine containing the toxic solvent diethylene glycol. This incident highlighted the global need for strict manufacturing standards.
In the late 1950s and early 1960s, the Contergan disaster in Germany underscored the dangers of inadequately tested medications. Thalidomide, marketed as Contergan, caused severe congenital disabilities, leading to the Kefauver-Harris Drug Amendment in 1962. This amendment required proof of a medication’s effectiveness and increased safety requirements, laying the foundation for statutory regulation of clinical studies and quality assurance in drug development.
The Birth of GMP
The 1906 Pure Food and Drug Act in the United States was one of the first laws to regulate the labelling and quality of drugs, banning the interstate commerce of misbranded and adulterated foods, drinks, and drugs. This act marked the beginning of federal involvement in ensuring drug safety and efficacy, laying the groundwork for future GMP regulations by establishing legal standards for drug quality and labelling.
Following the Sulfanilamide disaster, the Federal Food, Drug, and Cosmetic Act of 1938 was established, introducing requirements for pre-market safety testing of drugs. This legislation significantly expanded the FDA’s authority to regulate the pharmaceutical industry, paving the way for the development of broad GMP standards.
The Kefauver-Harris Amendments of 1962, enacted after the thalidomide disaster, mandated that drug manufacturers provide substantial evidence of the effectiveness and safety of their products before receiving FDA approval. This stage marked the formal beginning of GMP regulations by emphasising thorough scientific testing and quality assurance in pharmaceutical manufacturing.
In the United Kingdom, the Medicines Act of 1968 was a significant milestone, establishing the Committee on Safety of Medicines and introducing a comprehensive framework for the regulation of medicinal products. The act emphasised the importance of proper documentation, cleanliness, and staff training, laying the foundation for modern GMP practices.
World Health Organisation (WHO) GMP Guidelines
The World Health Organisation (WHO) formulated the first GMP guidelines in 1969 to ensure the traceability and quality of pharmaceutical production. Around the same time, the Pharmaceutical Inspection Convention was founded in Europe to supervise proper drug testing. These guidelines provided a standard for pharmaceutical manufacturers, emphasising quality assurance, validation, and documentation.
Modern-Era Reforms and Scandals Shaping GMP Practices
In 1978, GMP was codified in the US Code of Federal Regulations, and Germany enacted the Medicinal Products Act, revolutionising the drug market with strict requirements for production, approval, and handling of medicinal products. Throughout the 1980s and 1990s, incidents such as the Tylenol cyanide poisoning and the generic drug scandal highlighted the importance of GMP compliance and prompted regulatory reforms.
The establishment of the International Council for Harmonisation (ICH) in 1990 aimed to harmonise technical requirements for pharmaceuticals globally. Significant events in the early 2000s, including the Schering-Plough fine and the Vioxx recall, highlighted the financial and public health impacts of GMP violations. The heparin scandal in 2007-2008 emphasised the need for robust supply chain oversight.
Technological Advancements and GMP
The late 20th century experienced rapid technological advancements, significantly impacting GMP practices. Automation, computerised systems, and advanced analytical techniques improved the precision and efficiency of pharmaceutical manufacturing. For example, GlaxoSmithKline (GSK), one of the largest pharmaceutical companies in the United Kingdom, leverages advanced technologies to enhance its GMP compliance.
The Role of Regulatory Agencies
Regulatory agencies play a crucial role in the evolution of GMP. In the United Kingdom, the Medicines and Healthcare Products Regulatory Agency (MHRA) ensures pharmaceutical manufacturers comply with GMP standards through regular inspections and audits. Notable examples, such as the MHRA’s inspection of Wockhardt’s manufacturing facility in 2013, underscore the importance of regulatory oversight in maintaining GMP compliance.
Continuous Improvement and Modern GMP
The concept of continuous improvement is central to modern GMP. Pharmaceutical companies are encouraged to regularly review and update their manufacturing processes to ensure ongoing compliance and quality improvement. Initiatives like the International Conference on Harmonisation (ICH) guidelines promote adopting best practices across the industry.
Regulatory Framework and Guidelines
The United Kingdom’s GMP framework is governed by the MHRA, ensuring compliance with EU GMP guidelines aligned with WHO GMP standards. This regulatory oversight includes regular inspections, rigorous quality control, and comprehensive documentation.
Key Elements of GMP in the UK
- Quality Management Systems (QMS): Pharmaceutical companies maintain robust QMS to manage and document every aspect of production, including Standard Operating Procedures (SOPs), quality audits, and continuous improvement processes.
- Personnel Training and Qualification: Continuous training and development programs ensure personnel are competent to perform tasks according to GMP standards.
- Facility and Equipment Management: Facilities are designed and maintained to meet high standards of cleanliness and control, with equipment regularly calibrated and validated.
- Documentation and Record Keeping: Detailed documentation ensures traceability and accountability, essential for maintaining product quality and regulatory compliance.
- Risk Management: Risk management processes identify and mitigate potential risks in manufacturing, maintaining the safety, quality, and efficacy of pharmaceutical products.
- Control of Raw Materials: Strict controls ensure raw materials meet predefined quality criteria before use in production, with regular supplier audits.
- Production and Process Controls: The production process is tightly controlled, with in-process controls and batch records documenting every step.
- Validation and Qualification: Validation of processes, systems, and equipment ensures consistent delivery of products meeting specifications.
- Quality Control and Laboratory Testing: Comprehensive quality control measures involve rigorous testing of raw materials, in-process materials, and finished products.
- Handling of Complaints and Recalls: Effective systems handle product complaints and conduct recalls, protecting patient safety.
- Continuous Improvement: Regularly reviewing and updating processes, training, and systems drive continuous improvement.
Challenges and Future Directions
Despite significant progress, the pharmaceutical industry faces challenges in maintaining GMP compliance, such as integrating advanced technologies like artificial intelligence (AI) and blockchain. The future of GMP will likely involve greater collaboration between regulatory agencies, industry stakeholders, and technology providers.
Conclusion
The evolution of GMP in the pharmaceutical industry has been driven by regulatory changes, technological advancements, and lessons from past failures. From unregulated manufacturing to the modern era of continuous improvement, GMP ensures the quality, safety, and efficacy of pharmaceutical products. As the industry evolves, adopting advanced technologies and collaborative initiatives will be key to meeting future challenges and ensuring GMP success.
References
Astrazeneca. (2022). Innovating production and manufacture to meet the challenge of COVID-19. AstraZeneca – Research-Based BioPharmaceutical Company. https://www.astrazeneca.com/what-science-can-do/topics/technologies/innovating-production-and-manufacture-to-meet-the-challenge-of-covid-19.html
Bicycletherapeutics. (2022, July 20). Bicycle Therapeutics. https://www.bicycletherapeutics.com/
Covarrubias, C. E., Rivera, T. A., Soto, C. A., Deeks, T., & Kalergis, A. M. (2022). Current GMP standards for the production of vaccines and antibodies: An overview. Frontiers in Public Health, 10. https://doi.org/10.3389/fpubh.2022.1021905
Destro, F., & Barolo, M. (2022). A review on the modernization of pharmaceutical development and manufacturing – Trends, perspectives, and the role of mathematical modeling. International Journal of Pharmaceutics, 620, 121715. https://doi.org/10.1016/j.ijpharm.2022.121715
ElMaraghy, H., Monostori, L., Schuh, G., & ElMaraghy, W. (2021). Evolution and future of manufacturing systems. CIRP Annals, 70(2), 635-658. https://doi.org/10.1016/j.cirp.2021.05.008
EMC. (2022). All medicines for Martindale Pharma, an Ethypharm group company – (emc). electronic medicines compendium (emc). https://www.medicines.org.uk/emc/company/2380#gref
Gomez-Sanchez, R., Besley, S., Quayle, J., Green, J., Warren-Godkin, N., Areri, I., & Zeliku, Z. (2021). Maintaining a high-quality screening collection: The GSK experience. SLAS Discovery, 26(8), 1065-1070. https://doi.org/10.1177/24725552211017526
GSK. (2023). United Kingdom. https://www.gsk.com/en-gb/locations/united-kingdom/
Hikma. (2024). Operations. https://www.hikma.com/what-we-do/operations/
Jain, S. K., & Jain, R. K. (2017). Evolution of GMP in pharmaceutical industry. Research Journal of Pharmacy and Technology, 10(2), 601. https://doi.org/10.5958/0974-360x.2017.00118.4
Leading Minds Network. (2019). Lessons of GMP failures: Why it’s everyone’s business Part 1 of 3. Where Pharma & Life Science Leaders Meet LeadingMindsNetwork. https://www.leading-minds-network.com/en/article/lessons-of-gmp-failures-part-1-of-3
Morrison, I., Cork, H., Smith, P., Campbell, C., McTiernan, M., & White, K. (2020). Is the medicines and healthcare products regulator agency (Mhra) guidance on sodium Valproate acceptable to women of childbearing age? Journal of the Royal College of Physicians of Edinburgh, 50(2), 114-117. https://doi.org/10.4997/jrcpe.2020.207
Parry, D. (2019). Worldwide good manufacturing practices. Good Manufacturing Practices for Pharmaceuticals, 343-351. https://doi.org/10.1201/9781315120669-23
Pure Food and Drug Act (1906). (2016). The SAGE Encyclopedia of Pharmacology and Society. https://doi.org/10.4135/9781483349985.n340
Reinhardt, I. C., Oliveira, D. J., & Ring, D. D. (2020). Current perspectives on the development of industry 4.0 in the pharmaceutical sector. Journal of Industrial Information Integration, 18, 100131. https://doi.org/10.1016/j.jii.2020.100131
Singh, R. (2018). Automation of continuous pharmaceutical manufacturing process. Computer Aided Chemical Engineering, 431-446. https://doi.org/10.1016/b978-0-444-63963-9.00017-8
Woolf, A. D. (2022). Sulfanilamide (diethylene glycol) disaster—United States, 1937. History of Modern Clinical Toxicology, 139-148. https://doi.org/10.1016/b978-0-12-822218-8.00045-4